Haselmeier has a worldwide reputation for its patient-friendly, high-tech innovations. The new
Pergoveris® Pen, developed for its customer Merck, has once again confirmed the company’s
high standard of development.
The well-respected and listened to member of the medical device community, Paul Jansen, started in his new position as senior advisor on February 1, 2017. This appointment is a perfect fit to serve the objectives of Haselmeier AG as the innovation organization within the Haselmeier Group.
Haselmeier has not even officially presented its latest innovation and the D-Flex. Just one. has already won an award: The especially flexible disposable pen D-Flex has been given the GOOD DESIGN™ Award. However, the D-Flex stands out in the market primarily thanks to its uniqueness. No comparable product can be deployed so flexibly and at the same time deliver patient safety.
Haselmeier is pleased to announce that its newest production facility in Bengaluru (India) received its official certification from TÜV SÜD on 21st September 2016. Haselmeier is now in a position to supply the Asian market more easily and more effectively with medication dosage systems and, as a result, significantly improve life for patients.
There’s a lot happening at Haselmeier! As the next step in the consistent reorganisation process of the Haselmeier Group, some activities are being moved to other locations to guarantee greater focus on strategic and operative tasks.
Zurich, Switzerland, June 06, 2016 – Berlin-Chemie launched the new BerliPen® areo 3 on the German market in April 2016.
Continue reading “Haselmeier announces the German launch of the BerliPen® areo 3 through Berlin-Chemie”
Haselmeier announces the launch by Merck of their GONAL-f® 2.0 prefilled pen following approval by EMA, the European Medicines Agency.
The Haselmeier Group has decided to reinforce and reorganise its Executive Board.
Continue reading “Haselmeier Group Announces the Extension and Reorganization of its Executive Board”